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Background: Cystic Fibrosis (CF) is the most prevalent Mendelian disorder in European populations. Despite the fact that many Latin
American countries have a predominant population of European-descent, CF has remained an unknown entity until recently. Argentina and
Brazil have detected the first patients around three decades ago, but in most countries this disease has remained poorly documented. Recently,
other countries started publishing their results.
Methods: We present a compilation and statistical analysis of the data obtained in 10 countries (Argentina, Brazil, Chile, Colombia, Costa
Rica, Cuba, Ecuador, Mexico, Uruguay and Venezuela), with a total of 4354 unrelated CF chromosomes studied.
Results: The results show a wide distribution of 89 different mutations, with a maximum coverage of 62.8% of CF chromosomes/alleles in
the patient's sample. Most of these mutations are frequent in Spain, Italy, and Portugal, consistent with the origin of the European settlers. A
few African mutations are also present in those countries which were part of the slave trade. New mutations were also found, possibly
originating in America.
Conclusion: The profile of mutations in the CFTR gene, which reflects the heterogeneity of its inhabitants, shows the complexity of the
molecular diagnosis of CF mutations in most of the Latin American countries.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR mutations; Cystic Fibrosis; Latin America; Diagnosis; CFTR; Ethnic background; ABCC71. Introduction
The most frequent recessive genetic disorder in Caucasian
populations is Cystic Fibrosis (CF; MIM # 219700). The
incidence of the disease as well as the frequency of the most
common mutation, p.F508del, reflect ancient migratory and
demographic expansion processes, and possibly a selective
advantage of heterozygous carriers [1–6]. Extended haplotype
studies suggest that the p.F508del and a few other, common,
mutations originated between 11,000 and 34,000 years ago in a
population genetically different from any present-day Euro-⁎ Corresponding author. Tel.: +57 1 3165000x11614 or 11610; fax: +57 1
3165526.
E-mail address: gkeyeuxb@unal.edu.co (G. Keyeux).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.07.004pean group, and spread to different areas of Europe [3, 7].
Furthermore, some mutations were subject to founder and
genetic drift events, thus explaining regional and local elevated
frequencies [2,8,9].
Latin America and the Caribbean have become in the last
500 years a melting pot of different ethnicities.Many countries
have a strong Amerindian heritage mixed with Europeans
(predominantly Spanish or Portuguese, but also Italians,
Germans, French, English, near- and middle-Easterners and
central-European Jews), and in some of them (e.g. Cuba,
Colombia, Brazil), the predominant population in particular
regions is African-descended. The belief that CF was typically
a disease of northern Europeans and Anglo-Saxon descended
populations had misled the diagnosis in patients from Latin
America. However, the disease started to be studied in
Argentina in the sixties and later in the other countries [10].ed by Elsevier B.V. All rights reserved.
Table 1
Mutations found in the Latin American CF patients
Exon 1 p.L6V⁎
Exon 3 p.W57X, p.R75X, p.G85E
Exon 4 p.R117H
Exon 6a p.H199Y, p.V201M, p.L206W, p.Q220X, p.V232D,
c.846delT⁎
Exon 6b p.Y275X⁎, c.935delA
Exon 7 p.R334W, p.R347P, p.Y362X⁎ , c.1078delT,
c.1215delG
Exon 8 c.1323_1324insA⁎
Exon 9 c.1460_1461delAT⁎, c.1353_1354insT⁎,#
Exon 10 p.I506T, p.I507del, p.F508del
Exon 11 p.G542X, p.S549N, p.S549R, p.G551D, p.G551S,
p.R553X, p.L558S, p.A559T, c.1782delA
Exon 12 p.S589I
Exon 13 p.H609R⁎, p.P750L, p.V754M, c.1924_1930del,
c .2055_2063del , c .2183AA NG;c.2184delA,
c.2184delA, c.2185_2186insC, c.2347delG,
c.2566_2567insT⁎, c.2594_2595delGT⁎
Exon 14a p.R851L, c.2686_2687insT⁎
Exon 15 c.2869_2870insG
Exon 16 c.3120+1GNA
Exon 17a p.I1027T, c.3171delC, c.3199_3204del
Exon 17b p.G1061R, p.R1066C, p.W1069X#, p.W1089X,
p.Y1092X, p.W1098C⁎
Exon 19 p.R1162X, p.W1204X, p.Q1238X,
c.3617_3618delGA⁎#, c.3659delC
Exon 20 p.W1282X, p.R1283M
Exon 21 p.N1303K, c.4016_4017insT
Exon 22 c.4160_4161insGGGG⁎
5′ flanking c.-834GNT
Intron 2 c.297-1GNA⁎, c.297-2ANG
Intron 3 c.406-1GNA
Intron 4 c.621+1GNT
Intron 5 c.711+1GNT
Intron 8 c.IVS8-5T
Intron 10 c.1716GNA, c.1717-1GNA
Intron 11 c.1811+1.6KbANG, c.1812-1GNA
Intron 12 c.1898+1GNA, c.1898+3ANG
Intron 14 c.2789+2_2789+3insA, c.2789+5GNA
Intron 17a c.3272-26ANG
Intron 17b c.3500-2ANG⁎
Intron 19 c.3849+1GNA, c.3849+10KbCNT
Intron 20 c.4005+1GNA, c.4005-1GNA#
Mutations are listed according to their position in the gene. Mutation names
reported by the original authors have been changed to the new nomenclature,
according to the HGVS (2003) recommendations.
⁎: new mutations; #: mutations in the original author's paper included in the
present meta-analysis that have not been reported in the Cystic Fibrosis
Mutation Database.
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particular mutations, and only recently four Latin American
countries, namely Argentina [11, 12], Mexico [13], Colombia
[14] and Brazil [15], reported extensive CFTR locus (MIM #
602421) analyses. Still, few data are available for some of the
rest of the Latin American and Caribbean countries and for
others there are no data at all. In spite of this, a comprehensive
view of the disease incidence and most frequent mutations is
beginning to emerge in this region of the world.
Following the recommendations of a WHO workshop on
the worldwide molecular epidemiology of CF held in 2002
[16], the aim of the present investigation was to perform a
meta-analysis of the distribution of CFTR mutations across
the Central and South American sub-continent in order to
establish a comprehensive picture of the molecular epide-
miology of CF in this region. It should also help to design a
common diagnostic panel for the main mutations, as well as
regionally adapted additional mutation tests, according to the
results so far obtained.
DATABASES: OMIM: 602421 (CFTR); 219700 (CF);
http://www.sickkids.on.ca/cftr; GDB: 120584; XM_004980;
HGMD: CFTR; GeneCard: CFTR.
2. Materials
Data from patients from 10 Latin American countries
were taken from the literature. Since we believe it is
important to have as broad a picture as possible, some data
were taken from congress presentations, communications to
the Cystic Fibrosis Genetic Analysis Consortium (CFGAC;
Population variation of 24 common cystic fibrosis mutations.
Table 1.5. http://www.genet.sickkids.on.ca/cftr/newfreq/All.
html), or personal communications. A total of 4354 unrelated
CF chromosomes were studied between 1990 and 2004. The
information was gathered from 6 different CF studies from
Argentina, 10 from Brazil, 4 from Chile, 2 from Colombia, 2
from Mexico, 3 from Ecuador, 2 from Venezuela, and 1 each
from Costa Rica, Cuba, and Uruguay.
All mutations considered in the present survey are CF-
causing, as specified in the published articles. The
geographical origin of patients is as follows: Argentina:
Buenos Aires (N=49) [17]; Buenos Aires, La Plata (N=220)
[12]; Buenos Aires, Santa Fé, Mendoza, San Juan, Tucumán,
Córdoba, Entre Ríos, Corrientes, Formosa, Neuquen
(N=155) [18]; Buenos Aires, Formosa (N=111) (Varela
and Targovnik, personal communication); Buenos Aires
(N=13) [19]; Córdoba (N=75) (Oller-Ramirez, personal
communication); Brazil: Rio Grande do Sul, Santa Catarina,
Paraná, São Paulo, Minas Gerais (N=234) [20]; São Paulo
(N=37) [21]; São Paulo (N=160) [22]; Rio Grande do Sul
(N=61) [23]; Sao Paulo (N=60) [24]; Rio de Janeiro
(N=74) [25, 26]; Sao Paulo (N=24) [27]; Rio Grande do Sul
(N=77) [28]; Santa Catarina, Parana, Mina Gerais (N=193)
[15]; Sao Paulo (N=9) [29]; Chile: Santiago (N=36) [30];
Valparaíso (N=18) [31]; Santiago (N=22) [32]; Valdivia,
Santiago (N=50) [33]; Colombia: Bogotá, Antioquia,Caldas, Bolívar, Valle (N=92) [14]; Bogotá (N=17) [34];
Costa Rica: San José (N=24) [35]; Cuba: La Habana
(N=72) [36]; Ecuador: Quito (N=16) [37]; Guayaquil
(N=25) (Cassiman 2004, personal communication); Quito
(N=10) [38]; Mexico: Mexico DF (N=97) [13]; Monterrey,
Guadalajara, Puebla (N=40) [39]; Uruguay: Montevideo
(N=38) [40, 41]; Venezuela: Maracaibo (N=27) [34];
Caracas (N=41) [42].
The experimental methods used to analyse the CFTR
gene varied from one group to another. Some have
concentrated in the search of specific mutations that are
Table 2
Mutation frequencies in Latin American CF patients
Country No. of chromosomes
analysed
p.F508del p.G542X p.W1282X p.N1303K p.R1162X p.L6V⁎ p.W57X p.R75X p.G85E p.R117H p.H199Y p.V201M p.L206W p.Q220X p.V232D p.Y275X⁎ p.R334W p.R347P p.Y362X⁎ p.I506T
Argentina 98 61
440 258 18 12 12 2 1 1 3 1 5 1
310 181 20 7 5 5 7 0 5 0
222 135 15 7 5 1
26 14 2 1 1
150 88 6 6 1 2 3
Subtotal and
frequency (%)
1246
100
737
59.15
61
4.90
27
2.17
28
2.25
9
0.72
1
0.08
1
0.08
13
1.04
1
0.08
13
1.04
1
0.08
Brazil 468 221 26 11
74 38 2 1
320 155 28 3 8 8 4 1 2 1 1 8
122 62
120 38 10 3
148 38 4 0 0
48 15
154 75 5 1 0 2 0
386 154 24 6 10 17 9 0 10 1
18 4 0 0 2 0 0 0 0
Subtotal and
frequency (%)
1858
100
800
43.06
99
5.33
11
0.59
34
1.83
25
1.35
13
0.70
1
0.05
2
0.11
1
0.05
1
0.05
20
1.07
1
0.05
Chile 72 21
36 11 3 0
44 22 4 3 1 1
100 45 7 5 0 2 0 2 0
Subtotal and
frequency (%)
252
100
99
41.28
14
5.55
8
3.17
3
1.19
3
1.19
Colombia 184 77 7 2 1 2 1
34 13 2 1 1
Subtotal and
frequency (%)
218
100
90
41.28
9
4.13
3
1.38
2
0.92
2
0.92
1
0.46
Costa Rica
Frequency (%)
48
100
11
22.91
12
25.00
0 0 0 0 0
Cuba
Frequency (%)
144
100
49
34.03
Ecuador 32 11 1
50 16 2 2
20 5 0 0 0
Subtotal and
frequency (%)
102
100
32
31.37
2
1.96
1
0.98
2
1.96
Mexico 194 79 12 4 3 1 1 1 2
80 36 4 1
Subtotal and
frequency (%)
274
100
115
41.97
16
5.84
5
1.82
3
1.09
1
0.36
1
0.36
1
0.36
2
0.73
Uruguay
Frequency (%)
76
100
43
56.58
6
7.89
2
2.63
3
3.95
3
3.95
2
2.63
Venezuela 54 16 2
82 41
Subtotal and
frequency (%)
136
100
57
41.91
2
1.47
Total 4354 2033 221 49 72 42 1 1 3 32 1 1 1 2 1 1 1 39 1 1 2
Frequency (%) 100 46.69 5.08 1.13 1.65 0.96 0.02 0.02 0.07 0.73 0.02 0.02 0.02 0.05 0.02 0.02 0.02 0.90 0.02 0.02 0.05
The five most frequent mutations are shown on the left-hand side, followed by the rest of the mutations in 5′–3′ and exon–intron order. Where indicated, the mutation was screened and found in 0 chromosomes. The empty spaces indicate that the mutations were not tested.
Nomenclature of the mutations is according to the recent guidelines of the Human Genome Variation Society (2003) Nomenclature for the description of sequence variations. http://www.genomic.unimelb.edu.au/mdi/mutnomen/.
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p.I507del p.S549N p.S549R p.G551D p.G551S p.R553X p.L558S p.A559T p.S589I p.H609R⁎ p.P750L p.V754M p.R851L p.I1027T p.G1061R p.R1066C p.W1069X# p.W1089X p.Y1092X p.W1098C⁎ p.W1204X
3 0 1 0 1 1 1 1
1 0
4
1 2 3 1
3
0.24
1
0.08
1
0.08
6
0.48
2
0.16
1
0.08
1
0.08
4
0.32
1
0.08
1 4
1
2 1 1
0 0
0 1 0
0 0 1
1 0 1 0 2 0 1 3
0 0 0 0 0 0
1
0.05
1
0.05
1
0.05
10
0.54
1
0.05
2
0.11
3
0.16
3
0 0 0
1
0 1 1
2
0.79
4
1.58
4 1 1 1 1
4
1.83
1
0.46
1
0.46
1
0.46
1
0.46
0 0 0 0
0 0 0
5 5 1 1 1 1 1 1 1 1 1 1
1
5
1.82
6
2.19
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
0.36
1
1.31
1
1.31
1
1.31
10 6 6 6 1 22 1 1 2 1 1 1 1 1 1 6 1 3 5 1 1
0.23 0.14 0.14 0.14 0.02 0.51 0.02 0.02 0.05 0.02 0.02 0.02 0.02 0.02 0.02 0.14 0.02 0.07 0.11 0.02 0.02
(continued on next page)
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Mutation frequencies in Latin American CF patients
Country p.Q1238X p.R1283M c.-834GNT c.297-1GNA* c.297-2ANG c.406-1GNA c.621+1GNT c.711+1GNT c.846delT* c.935delA c.1078delT c.1215delG c.1323_1324insA* c.1353_1354insT*# c.1460_1461delAT*
Argentina
1 3 1 1
1 1 1
Subtotal and
frequency (%)
1
0.08
1
0.08
4
0.32
1
0.08
1
0.08
1
0.08
Brazil
1
1 1 1 0
0
Subtotal and
frequency (%)
1
0.05
2
0.11
1
0.05
Chile
0 0
Subtotal and
frequency (%)
Colombia 1 1
Subtotal and
frequency (%)
1
0.46
1
0.46
Costa Rica
Frequency (%)
0
Cuba
Frequency (%)
Ecuador
Subtotal and
frequency (%)
Mexico 1 3 1 2 1
1
Subtotal and
frequency (%)
1
0.36
3
1.09
1
0.36
1
0.36
2
0.73
1
0.36
Uruguay
Frequency (%)
1
1.31
Venezuela
Subtotal and
frequency (%)
Total 1 1 1 1 1 3 7 2 1 2 1 1 1 1 1
Frequency (%) 0.02 0.02 0.02 0.02 0.02 0.07 0.16 0.05 0.02 0.05 0.02 0.02 0.02 0.02 0.02
(continued )
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c.1716GNA c.1717-1GNA c.1782delA c.1811+1,6KbANG c.1812-1GNA c.1898+1GNA c.1898+3ANG c.1924_1930del c.2055_2063del c.2183AANG;c.2184delA c.2184delA c.2185_2186insC
5 1 4 1 1 1
0
1
2 2
6
0.48
1
0.08
6
0.48
2
0.16
1
0.08
1
0.08
1
0.08
1
0
6 5 1 3 0
0 0 0
7
0.37
5
0.27
1
0.05
3
0.16
0 0
12 1
12
5.50
1
0.46
0
0
1 1 2 2
1
0.36
1
0.36
2
0.73
2
0.73
1
1.31
1 14 1 18 5 3 1 1 2 6 1 1
0.02 0.32 0.02 0.41 0.11 0.07 0.02 0.02 0.05 0.14 0.02 0.02
(continued on next page)
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Table 2
Mutation frequencies in Latin American CF patients
Country c.2347delG c.2566_2567insT* c.2594_2595delGT* c.2686_2687insT* c.2789+2_2789+3insA c.2789+5GNA c.2869_2870insG c.3120+1GNA c.3171delC c.3199_3204del c.3272-26ANG c.3500-2ANG*
Argentina
2 1 2 2 3
3 1 1 2
Subtotal and
frequency (%)
2
0.16
1
0.08
2
0.16
2
0.16
6
0.48
1
0.08
1
0.08
2
0.16
Brazil
2 1 1 1
6
0 0 4
0
Subtotal and
frequency (%)
2
0.11
1
0.05
1
0.05
10
0.54
1
0.05
Chile
Subtotal and
frequency (%)
Colombia 1 1 1
Subtotal and
frequency (%)
1
0.46
1
0.46
1
0.46
Costa Rica
Frequency (%)
Cuba
Frequency (%)
Ecuador
Subtotal and
frequency (%)
Mexico 2
Subtotal and
frequency (%)
2
0.73
Uruguay
Frequency (%)
1
1.31
Venezuela
Subtotal and
frequency (%)
Total 2 2 1 3 2 9 1 12 1 2 2 1
Frequency (%) 0.05 0.05 0.02 0.07 0.05 0.21 0.02 0.28 0.02 0.05 0.05 0.02
(continued )
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c.3617_3618delGA*,# c.3659delC c.3849+1GNA c.3849+10kbCNT c.4005+1GNA c.4005-1GNA# c.4016_4017insT c.4160_4161insGGGG* c.IVS8-5T Unknown Authors
37 Aulehla-Scholz [17]
2 4 1 2 4 76 Visich [12]
1 78 Ibañez [18]
54 Varela 2004
8 Prieto [19]
2 1 1 1 18 Oller-Ramirez 2004
4
0.32
6
0.48
1
0.08
1
0.08
2
0.16
5
0.40
271
21.75
205 Raskin [20]
32 Chiba [21]
1 89 Bernardino [22]
60 Marostica [23]
69 Parizotto [24]
99 Cabello [25,26]
33 Martins [27]
70 Streit [28]
0 5 120 Raskin [15]
0 0 12 Goloni-Bertollo [29]
1
0.05
5
0.27
789
42.46
48 Rios [30]
22 Molina [31]
1 11 Navarro [32]
0 3 34 Repetto [33]
4
1.58
115
45.63
1 67 Keyeux [14]
17 Restrepo [34]
1
0.46
84
38.53
0 25
52.08
Venegas [35]
95
65.97
Collazo [36]
20 Merino [37]
30 Cassiman 2004
15 Paz-y-Mino [38]
65
63.72
1 1 53 Orozco [13]
2 35 Villalobos [39]
3
1.09
1
0.36
88
32.11
11
14.47
Luzardo [40,41]
36 Restrepo [34]
41 Alvarado [42]
77
56.62
1 4 1 18 1 1 2 1 5 1620
0.02 0.09 0.02 0.41 0.02 0.02 0.05 0.02 0.11 37.21
Mutation frequencies in Latin American CF patients
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polymerase chain reaction (AS-PCR), enzymatic digestion,
allele specific oligonucleotide hybridization (ASO), or using
mainly commercial kits, whereas other studies used a sys-
tematic approach to analyse the promoter, coding and exon/
intron boundaries of the CFTR region in the search for any
possible mutation. The methods used in the latter include
Denaturing Gradient Gel Electrophoresis (DGGE), Single
Strand Conformational Polymorphism (SSCP) and Hetero-
duplex Analysis methods, followed by sequencing of the
observed electrophoretical variants [11–15].
2.1. Statistical analyses
The genetic structure of the groups of patients was anal-
yzed by AMOVA (Analysis of Molecular Variance), using
the Arlequin Ver 2.000 software [43], in order to test the
genetic variance in the distribution of CF-causing mutations
by country.
Dendrograms were constructed using the UPGMA (Un-
weighted Pair Group Method with Arithmetic Mean) and NJ
(Neighbour Joining) methods with Reynolds' distance to
visualize the differences in the distribution of the CFTR
mutations in the Latin American countries so far studied.
These were constructed using Arlequin to calculate the pair-
wise Fst, and the Populations [44] and TreeView (Win32)
[45] programs to build the dendrograms.
3. Results
Out of 4354 CF chromosomes, 89 mutations were found
(Table 1) with a detection rate of 62.79% of the total CF
chromosomes studied. The frequency data obtained from this
compilation are summarized in Table 2.
As expected, the p.F508del is the most frequent mutation,
with an average frequency of 46.69% (2033/4354 chromo-
somes). Nevertheless, the range is broad, from 22.92% in
Costa Rica to 59.15% in Argentina (Table 3). The p.G542X
mutation, with a total frequency of 5.07% (25% in Costa Rica
to 1.47% in Venezuela), is the second most frequent mutation
in Latin America, with the exception of Colombia and Costa
Rica. p.N1303K, p.W1282X and p.R1162X are the next most
frequent mutations, with variations from 0.59% to 3.95%
(Table 3). Costa Rica is a unique case, where p.G542X (12/48
chromosomes) and p.F508del (11/48 chromosomes) have
almost the same frequencies. In Colombia, the second muta-
tion is c.1811+1.6KbANG, with a frequency of 5.5% (12/
218 chromosomes) (Table 2). The p.G85E mutation was
found in several countries such as Argentina [[12,18,19],
Oller Ramirez, personal communication], Brazil [15,22],
Ecuador (Cassiman, 2004, personal communication), Mex-
ico [13] and Uruguay [41] with frequencies ranging from
0.36% in Mexico up to 3.95% in Uruguay. The frequency of
the rest of the mutations varies from one country to another,
and many are restricted to one or two countries only (Tables 2
4 and 5).From the 89 mutations found, 41 are present in more than
1 patient (Table 2). As shown in Table 4, 19 of them have
overall frequencies of 0.1% to 1% in Latin America and could
be considered as rare, but some of them have local elevated
frequencies, like c.1811+1.6KbANG in Colombia (from
4.2% to 10.5% in the different geographical regions studied)
[14, 46], p.G85E in Ecuador (8.9%) (Ruiz et al., personal
communication), Uruguay (3.95%) [41], Brazil (2.33%) [15]
and Argentina (2.26%) [18], p.R334W in Brazil (2.6%) [15,
22] and p.I507del (2.58%) and p.S549N (2.5%) in Mexico
[13] (Table 2). p.R1162X showed an overall frequency of
0.96% (Table 3), but with some regional elevated frequen-
cies, like in Santa Catarina, Brazil, with a presence of 10.4%
in the sample studied [15]. c.3120+1GNA, normally present
in African and Afrodescendant populations, was found in Rio
de Janeiro, Brazil, with a frequency of 4.05% [26].
So far, 48mutations are present only once in thewhole set of
chromosomes (4354), and 16 of them have not been described
in other populations (mutations c.1460_ 1461delAT⁎,
c.2566_2567insT⁎, p.L6V⁎, p.Y362X⁎,⁎c.1353_1354insT⁎,
c .2594_2595delGT⁎ , p .W1098C⁎ , c .846de lT⁎ ,
c.4160_4161insGGGG⁎, c.297-1GNA⁎, c.3617delGA⁎,
c.2686_2687insT⁎, p.Y275X⁎, c.3500-2ANG⁎, p.H609R⁎
and c.1323_1324insA⁎) (Table 5B).
The p.G551D mutation, which shows an elevated fre-
quency in the world, was found only in one Argentinean [18],
two Brazilian [20,25], two Chilean [33, 32] and one Mexican
[13] patient. p.R117H, a frequent mutation in the British
patients, was investigated in the patients from Argentina [[18],
Varela and Targovnik, personal communication], Brazil
[15,28,29], Colombia [14], Costa Rica [35] and Mexico
[13], and was found only in one CF patient from Mexico.
Nevertheless, it was found in 2 patients from a sample of 35
Argentinean males with congenital bilateral absence of the vas
deference [47]. Finally, the percentage of unidentified
mutations in the whole sample of Latin American patients is
37.21% (Tables 2 and 3). However, four countries are far away
from this mean value (Costa Rica, Cuba, Ecuador and
Venezuela), and only two, Argentina (21.75%) and Uruguay
(14.47%), have lower percentages of unknown mutations.
At least another 38 mutations have been searched for, but
none of them were found in the CF patients from Latin
America: p.E60X, p.Y122X, p.G178R, p.G330X, p.R347H,
p.R352Q, p.S364P, p.A455E, p.Q493X, p.V520F, p.C524X,
p.R560T, p.Y563D, p.P574H, p.K710X, p.Q890X, p.
R1158X, p.S1196X, p.S1255X, p.D1270N, p.W1310X, p.
W1316X, c.405+1G-A, c.444delA, c.556delA, c.574delA,
c.1677delTA, c.2043delG, c.2307insA, c.2909delT,
c.3120G-A, c.3358delAC, c.3662delA, c.3750delAG,
c.3791delC, c.3821delT, c.3849+4A-G, c.3905insT.
For the calculation of the distance matrix used in the
AMOVA analyses and the construction of dendrograms, we
included the frequency data of all mutations greater or equal
to 0.1% (Tables 3 and 4), of the very rare mutations listed in
Table 5, grouped as a single set of “other” mutations,
different in each country, and of the unknown mutations.
Table 3
Most frequent mutations (N1%) in Latin American patients
Country Chromosomes
analysed
p.F508del p.G542X p.N1303K p.W1282X p.R1162X Unknown
n % n % n % n % n % n %
Argentina 1246 737 59.15 61 4.90 28 2.25 27 2.17 9 0.72 271 21.75
Brazil 1858 800 43.06 99 5.33 34 1.83 11 0.59 25 1.35 789 42.46
Chile 252 99 39.28 14 5.55 0 0.00 8 3.17 3 1.19 115 45.63
Colombia 218 90 41.28 9 4.13 2 0.92 3 1.38 2 0.92 84 38.53
Costa Rica 48 11 22.92 12 25.00 – – – – – – 25 52.08
Cuba 144 49 34.03 – – – – – – – – 95 65.97
Ecuador 102 32 31.37 2 1.96 1 0.98 – – – – 65 63.72
Mexico 274 115 41.97 16 5.84 5 1.82 – – – – 88 32.11
Uruguay 76 43 56.58 6 7.89 2 2.63 – – 3 3.95 11 14.47
Venezuela 136 57 41.91 2 1.47 – – – – – – 77 56.62
Total 4354 2033 46.69 221 5.08 72 1.65 49 1.13 42 0.96 1620 37.21
A – sign indicates that these mutations were not tested in the sample of patients, therefore their real frequency remains unknown.
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tiation of the CF-causing mutations [48] were found between
the Argentinean and Uruguayan (FST=0.00187, pN0.18),
the Brazilian and Chilean (FST=0.00088, pN0.20), the
Brazilian and Colombian (FST=0.0028, pN0.19) and the
Cuban and Ecuadorian (FST=− 0.0062, pN0.69) patient
groups. On the contrary, some of the other group
comparisons show moderate to elevated genetic differences
between each other (FST=0.05–0.23, pN0.000), such as in
the case of Uruguay or Argentina versus Costa Rica, Cuba,
Ecuador and Venezuela, indicating that the mutations
contributing to the disease are significantly different between
any of the latter four countries and Argentina or Uruguay.
The dendrograms maintain the same clustering pattern
with the different methods used, indicating the strength and
good resolutions of the methods employed. Fig. 1 shows the
results obtained with the UPGMA method using Reynolds'
distance. Reflecting the FST data, Argentina and Uruguay,Table 4
Mutations with frequencies between 0.1% and 1%
Mutation Frequency
Number of chromosomes %
p.R334W 39 0
p.G85E 32 0
p.R553X 22 0
c.1811+1.6KbANG 18 0
c.3849+10KbCNT 18 0
c.1717-1GNA 14 0
c.3120+1GNA 12 0
p.I507del 10 0
c.2789+5GNA 9 0
c.621+1GNT 7 0
p.S549N 6 0
p.S549R 6 0
p.G551D 6 0
p.R1066C 6 0
c.2183ANG;c.2184delA 6 0
p.Y1092X 5 0
c.1812-1GNA 5 0
c.IVS8-5T 5 0
c.3659delC 4 0Chile, Brazil and Colombia, and Cuba, Ecuador and Vene-
zuela form separate clusters and show very short branching
distances within each cluster, due to a large similarity in the
type and frequency of the CF-causing mutations. Costa Rica
sits on an isolated branch, apparently due to the weight given
by the exceptionally high frequency of the p.G542Xmutation
in these patients (25%). Although some of the clustering
could be artificial, due to the lack of mutation data in some
countries (e.g. Cuba, Costa Rica and Venezuela), it is clear
that the general pattern will be maintained for those countries
where a great number of mutations as well as a significant
number of patients have been studied.
4. Discussion
In the present meta-analysis we have examined the results
obtained in the research of 4354 CF chromosomes from
Latin American patients, where 89 mutations were found.Country
.90 Argentina, Brazil, Chile, Colombia, Uruguay
.73 Argentina, Brazil, Ecuador, Mexico, Uruguay
.51 Argentina, Brazil, Chile, Mexico, Uruguay
.41 Argentina, Colombia
.41 Argentina, Mexico
.32 Argentina, Brazil, Uruguay
.28 Argentina, Brazil Colombia
.23 Brazil, Mexico, Uruguay
.21 Argentina, Brazil, Colombia, Uruguay
.16 Argentina, Brazil, Mexico
.14 Mexico
.14 Argentina, Brazil, Colombia
.14 Argentina, Mexico
.14 Argentina, Colombia, Mexico
.14 Argentina, Mexico
.11 Colombia, Mexico
.11 Brazil
.11 Argentina
.09 Argentina
Table 5
Mutations with frequencies less than 0.1%
Panel A
Mutation Number of
chromosomes
% Country
p.R75X 3 0.07 Mexico
c.W1089X 3 0.07 Argentina,
Brazil
c.406-1GNA 3 0.07 Mexico
c.1898+1GNA 3 0.07 Argentina,
Brazil
c.2686_2687insT⁎ 3 0.07 Argentina,
Brazil
p.L206W 2 0.05 Brazil
p.I506T 2 0.05 Mexico
p.S589I 2 0.05 Argentina
c.711+1GNT 2 0.05 Argentina
c.935delA 2 0.05 Mexico
c.2055_2063del 2 0.05 Mexico
c.2347delG 2 0.05 Brazil
c.2566_2567insT⁎ 2 0.05 Argentina
c.2789+2_2789+3insA 2 0.05 Argentina
c.3199_3204del 2 0.05 Mexico
c.3272-26ANG 2 0.05 Argentina
c.4016_4017insT 2 0.05 Argentina
Panel B
Mutation N %
each
Country
p.L6V⁎, p.W57X, p.Q220X, p.Y362X⁎, p.I1027T, p.G1061R, p.R1283M, c.297-2ANG, c.1353_1354insT⁎,
c.1460_1461delAT⁎, c.1782delA, c.1898+3ANG, c.2184delA, c.2594_2595delGT⁎, c.2869_2870insG,
c.4005⁎1GNA, c.4005-1GNA#
17 0.02 Argentina
p.R117H, p.H199Y, p.G551S, p.L558S, p.P750L, p.V754M, p.W1069X#, p.W1098C⁎, p.W1204X, c.297-1GNA⁎,
c.846delT⁎, c.1078delT, c.1716GNA, c.1924_1930del, c.4160_4161insGGGG⁎
15 0.02 Mexico
p.V201M, p.V232D, p.Y275X⁎, p.R347P, p.R851L, p.Q1238X, c.3171delC, c.3617_3618delGA⁎# 8 0.02 Brazil
p.A559T, p.H609R⁎, c.1215delG, c.1323_1324insA⁎, c.2185_2186insC, c.3500-2ANG⁎, c.3849+1GNA, 7 0.02 Colombia
c.-834GNT 1 0.02 Uruguay
The upper part (Panel A) shows the mutations found in more than one patient, whereas the lower part (Panel B) of the table shows all the mutations that are
present only once in each country. N=number of different mutations.
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have started molecular studies in their patients with a
probable Cystic Fibrosis diagnosis. Also, the method used to
investigate the CFTRmutations varied from one group to the
other: some authors have concentrated in the search of
specific mutations that are most frequently found in
Caucasians (using mainly commercial kits), whereas other
studies made a systematic analysis of part or all the coding
region of the CFTR gene (DGGE, SSCP or mHET methods,
followed by sequencing). Therefore, not all studies can be
directly compared one to another, and most important, at
present it is not possible to know if the absence of particular
mutations is real, or results from a screening bias. However,
this is the most complete compilation of the Latin American
CF-causing mutations, and the general trend deduced in the
present study is consistent with the data presented in the first
survey of 2174 CF chromosomes prepared by the authors for
a meeting convened by the World Health Organization in
2002 [16].The profile of mutations in the CFTR gene in the different
countries and areas reflects the heterogeneity of its
inhabitants, since Latin America is a region that shows a
very strong diversity in certain features such as population
origin, cultural aspects and environment. In Mexico,
Colombia, Ecuador or Chile, for instance, between 57%
and 85% of the population is Mestizo, which means that it is
a highly admixed population between Europeans (mainly
Spaniards), Amerindians and, in some regions, Afrodescen-
dants. This is clearly reflected in the mitochondrial DNA
haplogroups found in the Mestizo population from Mexico
and Colombia, for example, where up to 78% of the
maternally inherited lineages are Amerindian (A-D) [49, 50].
As a consequence, the frequencies of the CF mutations differ
significantly between the South-eastern countries (Argen-
tina, Uruguay and south eastern of Brazil), which have had
the major European immigration, and the others.
As an example, in the case of Argentina and Uruguay, the
p.F508del mutation shows the highest frequencies (59% and
Fig. 1. UPGMA dendrogram using Reynolds' distance. The tree shows the
clustering of CF patients according to the CF-causing mutations found in
each country (Arg=Argentina, Bra=Brazil, Chi=Chile, Col=Colombia,
CR=Costa Rica, Cu=Cuba, Ecu=Ecuador, Mex=Mexico, Uru=Uruguay,
Ven=Venezuela).
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ancestry. Furthermore, if we take three of the most frequent
mutations in Europeans (p.F508del, p.G542X and p.
N1303K), along with a very frequent mutation in Italians,
p.R1162X [9], the percentage of these in Argentinean and
Uruguayan CF patients adds up 67% and 71%, respectively,
of the mutations (Table 3). This is also manifest in Brazil,
where the States that have a predominant European ancestry
with little admixture with Africans or Amerindians (Santa
Catarina, Parana) show a frequency of 63% for these
mutations, compared to 14% in the Afro-Brazilian patients
[15].Table 6
Screening panel of CFTR mutations
Country Total number of mutations Minimum panel
Uruguay 12 6 mutations: p.F508del, p.G542X, p.R1
Argentina 52 7 mutations: p.F508del, p.G542X, p.R1
México 35 8 mutations: p.F508del, p.G542X, p.N
c.3849+10kbGNA)
Colombia 19 7 mutations: p.F508del, p.G542X, p.R1
Brazil 41 6 mutations: p.F508del, p.G542X, p.R1
The total number of mutations found in each country is indicated in the second col
indicated in the third column: this minimum panel of CF-causing mutations includes
close or above 1% in the population considered, indicated in parenthesis. The last cAnother feature of Latin American countries with higher
European descent, is the lower frequency of unknown
mutations, as seen in Argentina (22%) and Uruguay (14%)
(Table 3), and in the more European States from Brazil
(19%) [15], which is comparable to the global value given
for Europe (18%), particularly for Spain, France, Germany
and the United Kingdom [9]. Even if this overall observation
could partly be due to a better CF diagnosis, particularly in
Argentina where the clinical expertise has been developed
over decades, this does not seem to explain the significant
differences observed in some other countries, like Colombia
(39% unknown mutations), for instance, where patients with
borderline or normal sweat test values and mild clinical signs
were indeed found to have rare mutations in the CFTR locus
[14]. Therefore, we presume that among the true unknown
CF genotypes, a high number of mutations are probably
contained in the unexplored regions of the gene (deep
intronic sequences and 5′ and 3′ regulatory regions).
The ethnic background of the different Latin American
CF patients and the diversity of origin of the European
ancestors is also apparent in the rest of the profile of CFTR
mutations so far found: the rare mutations (b1%) are very
different in each country, and many of them are present in
only one country, as shown in Tables 4 and 5. Furthermore,
each of the four countries where an exhaustive search for
mutation has been achieved (Argentina, Brazil, Colombia
and Mexico), shows a set with a high number of private
mutations, present in only one patient (Table 5, panel B).
In particular regions from Colombia, Venezuela, Brazil,
Uruguay and Ecuador, the presence of Afrodescendant
populations is important, although its global percentage does
not exceed 10%. Anthropological and genetic studies,
however, show that in some countries like Colombia, the
African component is present in up to 25% of the population
[51], it being in the Mulattos or in the Mestizo. Actually, two
African mutations (p.A559T and c.3120+1GNA) have been
found in two regions with high African admixture in
Colombia (Bolivar and Antioquia-Chocó) [14], and the
c.3120+1G-NA mutation has also been found in Brazil [15,
26], with a frequency of 4% in Rio de Janeiro, and Argentina
(Oller Ramirez, personal communication). As discussed,
another way to disclose similarities or differences in the
distribution of mutations in the CF patients from LatinDetection
power
162X, p.N1303K (p.R334W, p.G85E) 78%
162X, p.W1282X, p.N1303K (p.R334W, p.G85E) 71%
1303K (p.R75X, p.I507del, p.S549N,c.406-1GNA, 58%
162X, p.W1282X, p.N1303K (p.S549R, c.1811+1.6kbANG) 56%
162X, p.W1282X, p.N1303K (p.R334W) 53%
umn from left. The number of mutations useful in a first routine screening is
all those mutations shown in Table 3 and other mutations having a frequency
olumn shows the detection power reached, when using this minimum panel.
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diversity found in the series of patients grouped by country.
This statistical analysis gives a numerical value (Fst) to the
differences in the mutations observed in the groups of
patients. The separate branch formed by Ecuador, Cuba and
Venezuela (Fig. 1) probably reflects this contribution of
African genes, since the patients from Ecuador (Guayaquil)
[[37], Cassiman, personal communication] and Venezuela
(Maracaibo) [34] come from regions with high admixture
with Africans. Descendants of people from the Middle East
are also numerous in these same regions, and thus could
partly explain the distinct clustering. In other words,
although the specific mutations found in Afrodescendant
CF patients have not been screened for in the Ecuadorian,
Cuban and Venezuelan CF patients, the present analysis
shows that, even with the scarce data available to date, their
genetic makeup, as regards the CF-related mutations, is
distinct from that of the rest of Latin American countries.
Contrary to the argument sometimes found in the
literature, we do not believe that the discrete clustering of
Mexico, Brazil, Chile and Colombia, but also Ecuador, Cuba
and Venezuela (Fig. 1), reflects a more indigenous
contribution to the CF mutation panel, which could have
been overlooked by the actual methods used to screen the
patients. Asia, which is the major source of the Native
Americans, is not a region with a particularly high incidence
of CF, nor have the frequent “Asian”mutations [52–54] been
found in Latin American patients, as has been the case with
the African and Afro-American mutations [54–57]. New
mutations found in the Latin American patients could be
regarded as genuine “American” private mutations (unless
they are found in patients of the source populations), and the
actual number (16 in 4356 chromosomes) could be
suggestive of other private mutations not detected so far.
The case of Costa Rica is unusual, since although being
one of the most “European” countries in Latin America
(sometimes called the Latin-American Switzerland), only
two common European mutations, from a panel of 16
frequent mutations, were found [35], and a high proportion
of mutations (52%) remain unknown. In this country, p.
G542X (25%) is the first mutation, followed by p.F508del
(22.92%) (Table 3). As argued by the authors, this unusual
high frequency of p.G542X, which is almost four times that
observed overall in Spain (7.66%) and Andalusia (8.6%) [9],
could be a consequence of a strong founding effect due to the
small number of settling families from this region established
in Costa Rica in the XVIth–XVIIth century. Due to this, a
part of this elevated frequency can also be attributed to
endogamy for many generations, and thus non-randomness
of the patients studied. Another example of a possible
founder effect has been observed in Colombia, where two
mutations show unusually high frequencies, c.1811+
1,6kbANG (10.8%) in Bogotá [14], and c.621+1GNA
(17.65%) in Boyacá [Mateus et al., unpublished results].
We constructed dendrograms using the pairwise genetic
distances obtained using both, a reduced (consisting of 2174CF chromosomes) [16] and an enlarged set of patients
(present data). The only relevant difference observed when
using a higher number of patients per country is a shift in the
clustering of the Chilean CF cohort, which in the first study
[30] had a similar mutation profile as Cuba, and clustered
together with these patients on a separate branch (data not
shown). We therefore believe that the actual grouping shown
in the dendrograms (Fig. 1) not only is a reliable view of the
origin of the mutations in the different Latin American
countries, but also, and more important, points to the need of
a diversity of mutation panels advisable to reach a better
diagnostic efficacy. Argentina and Uruguay should screen a
common panel of 7 mutations which would reach a detection
power of 71% and 78%, respectively, of the CF mutations.
This panel, besides the common mutations shown in Table 3,
should include the p.R334W and p.G85E mutations. Brazil,
using the same panel, would reach only 53% of detection
(Table 6), the rest of the mutations being present at fre-
quencies of b0.6% in the whole sample. The situation of
Colombia and Mexico is quite different, since the minimum
panel includes the common mutations (Table 3) plus a set of
other mutations (5 in Mexico and 2 in Colombia), which are
different in each of the two countries (Table 6).
In conclusion, the present meta-analysis shows the
complexity of the molecular diagnosis of CF mutations in
most of the Latin American countries. Therefore, the
knowledge of the molecular genetic epidemiology of CF in
the different countries is important to schedule more
straightforward molecular diagnostic of the patients in
order to improve the cost-effectiveness of the studies,
especially when economical resources are scarce. From a
clinical point of view, a first screen should include the main
mutation panel described in Table 6, after which a locally
(geographically) adapted choice of other relevant regions of
the CFTR gene to be screened (particular mutations, or exons
and exon/intron boundaries) seems advisable in those
patients where the genotype remains unknown after the
basic panel screening, like for instance the p.R553X
mutation in Sao Paulo [20] and Formosa (Varela and
Targovnik, personal communication), since otherwise an
important proportion of mutations in these patients could be
overlooked.
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